| ￥3300 | |
| Z05709-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 22.29 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 22.29 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of NRAS, His, Human is greater than 90% as determined by SEC-HPLC. »
NRAS, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | NRas is a key mediator of the mitogenic pathway in normal cells and in cancer cells. Its dynamics and nanoscale organization at the plasma membrane (PM) facilitate its signaling. NRas activity is mediated and regulated by its dynamic interactions with functional (Grb2, BRAF, NF1, and GPI-nucleated) clusters at the PM. |
| Synonyms | GTPase NRas; N-Ras; HRAS1; ALPS4; CMNS; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
